Photographer: David Paul Morris/Bloomberg

Gilead Judge Re-Opens Case Amid Claim Merck Scientist Lied

Updated on
  • Witness is accused of deceiving jury about origins of patent
  • Merck was awarded $200 million in fight over hepatatis C cure

A federal judge re-opened Merck & Co.’s patent case against Gilead Sciences Inc. over a hepatitis C drug amid claims that an ex-Merck scientist lied to a jury that awarded the company $200 million in damages.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.